VIDEO: Finerenone induced reduction in albuminuria for patients with CKD, diabetes
George L. Bakris, MD, a professor of medicine and the director of the American Heart Association-accredited Comprehensive Hypertension Center, University of Chicago Medicine, spoke about a new subgroup analysis of the FIGARO-DKD trial.
Researchers presented the secondary kidney outcomes of FIGARO-DKD, a randomized, double-blind, placebo-controlled phase 3 trial, at ASN Kidney Week. They found finerenone induced a pronounced reduction in albuminuria for patients with stage 1-4 chronic kidney disease and type 2 diabetes.
“Bottom line is that there was a 23% risk reduction in doubling of creatinine. Number two, and I think more important, there was a 20% reduction in time to dialysis. So, we reduced the time to dialysis by 20% in these people that did not necessarily have advanced kidney disease. They had eGFRs in the 60s with microalbuminuria,” he said.